Literature DB >> 25782411

The novel role of miRNAs for tamoxifen resistance in human breast cancer.

Wenwen Zhang1, Jing Xu, Yaqin Shi, Qian Sun, Qun Zhang, Xiaoxiang Guan.   

Abstract

The selective estrogen receptor modulator tamoxifen is the most commonly used treatment for patients with ER-positive breast cancer. However, tumor cells often develop resistance to tamoxifen therapy, which is a major obstacle limiting the success of breast cancer treatment. miRNAs, as oncogenic or tumor suppressor genes, regulate the expression and function of their related target genes to affect the biological behaviors of cancer cells, including cancer initiation, progression, metastasis, and therapeutic resistance. In detail, many miRNAs associated with breast cancer tamoxifen resistance have been identified, which offer new targets for breast cancer therapy. Here, we review the miRNAs involved in regulation of tamoxifen resistance in human breast cancer and the mechanism of how the modulation of miRNAs may regulate the sensitivity of breast cancer cells to tamoxifen. We also discuss the future prospects of studies about miRNAs in regulation of tamoxifen resistance and miRNA-based therapeutics for tamoxifen resistance breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25782411     DOI: 10.1007/s00018-015-1887-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  83 in total

1.  A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Authors:  Michele De Laurentiis; Grazia Arpino; Erminia Massarelli; Angela Ruggiero; Chiara Carlomagno; Fortunato Ciardiello; Giampaolo Tortora; Diego D'Agostino; Francesca Caputo; Giuseppe Cancello; Emilia Montagna; Luca Malorni; Luigia Zinno; Rossella Lauria; Angelo Raffaele Bianco; Sabino De Placido
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

2.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

Authors:  X Yang; D L Phillips; A T Ferguson; W G Nelson; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 3.  MicroRNAs and cancer: past, present, and potential future.

Authors:  Kristen M Nelson; Glen J Weiss
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

4.  Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.

Authors:  Virginia G Kaklamani; Mary Cianfrocca; Jennifer Ciccone; Kelly Kindy; Alfred Rademaker; Elizabeth L Wiley; William Gradishar; Ruth M O'Regan
Journal:  Biomarkers       Date:  2010-03       Impact factor: 2.658

5.  Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Authors:  Margaretha Rudas; Martina Lehnert; Anh Huynh; Raimund Jakesz; Christian Singer; Sigurd Lax; Walter Schippinger; Otto Dietze; Richard Greil; Wolfgang Stiglbauer; Werner Kwasny; Renate Grill; Michael Stierer; Michael F X Gnant; Martin Filipits
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

6.  Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Authors:  Diana M Cittelly; Partha M Das; Virgilio A Salvo; Juan P Fonseca; Matthew E Burow; Frank E Jones
Journal:  Carcinogenesis       Date:  2010-09-27       Impact factor: 4.944

7.  Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Authors:  Jozien Helleman; Maurice P H M Jansen; Kirsten Ruigrok-Ritstier; Iris L van Staveren; Maxime P Look; Marion E Meijer-van Gelder; Anieta M Sieuwerts; Jan G M Klijn; Stefan Sleijfer; John A Foekens; Els M J J Berns
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

8.  MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.

Authors:  Tyler E Miller; Kalpana Ghoshal; Bhuvaneswari Ramaswamy; Satavisha Roy; Jharna Datta; Charles L Shapiro; Samson Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2008-08-15       Impact factor: 5.157

9.  MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.

Authors:  Peter Olson; Jun Lu; Hao Zhang; Anny Shai; Matthew G Chun; Yucheng Wang; Steven K Libutti; Eric K Nakakura; Todd R Golub; Douglas Hanahan
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

Review 10.  Use of tamoxifen for breast cancer: twenty-eight years later.

Authors:  I A Jaiyesimi; A U Buzdar; D A Decker; G N Hortobagyi
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

View more
  8 in total

1.  MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.

Authors:  Dan Wang; Jin Ren; Hui Ren; Jin-Ling Fu; Dan Yu
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

2.  Aminoflavone upregulates putative tumor suppressor miR-125b-2-3p to inhibit luminal A breast cancer stem cell-like properties.

Authors:  Nicole Mavingire; Petreena Campbell; Tiantian Liu; Jonathan Wooten; Salma Khan; Xin Chen; Jason Matthews; Charles Wang; Eileen Brantley
Journal:  Precis Clin Med       Date:  2022-03-28

3.  Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.

Authors:  Fei Long; Ye He; Haoyu Fu; Yun Li; Xubin Bao; Quanren Wang; Yigang Wang; Chengying Xie; Liguang Lou
Journal:  Cancer Sci       Date:  2019-02-26       Impact factor: 6.716

Review 4.  Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.

Authors:  Esmael Besufikad Belachew; Dareskedar Tsehay Sewasew
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-25       Impact factor: 5.555

5.  MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH.

Authors:  Yike Wang; Lifeng Dong; Fang Wan; Fangfang Chen; Dianlei Liu; Deqin Chen; Jingpei Long
Journal:  Cell Death Dis       Date:  2021-09-22       Impact factor: 8.469

Review 6.  Tamoxifen Resistance: Emerging Molecular Targets.

Authors:  Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

7.  c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis.

Authors:  Wenfei Ji; Wenwen Zhang; Xin Wang; Yaqin Shi; Fang Yang; Hui Xie; Wenbin Zhou; Shui Wang; Xiaoxiang Guan
Journal:  Cell Death Dis       Date:  2020-09-15       Impact factor: 8.469

Review 8.  miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.

Authors:  Erik Kudela; Marek Samec; Lenka Koklesova; Alena Liskova; Peter Kubatka; Erik Kozubik; Tomas Rokos; Terezia Pribulova; Eva Gabonova; Marek Smolar; Kamil Biringer
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.